Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase 2 5Phase EARLY_PHASE1 3Phase 3 2Phase 1 2Phase 4 1Phase 2/3 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Cognitive Dysfunction 1

Interventions

Magnetic Resonance Spectroscopy 23Metformin 14pembrolizumab 12Radiotherapy 12Biopsy 11Nivolumab 9Fluorouracil 9Cyclophosphamide 9Temozolomide 7Radiation 7Bevacizumab 7gallium 68 PSMA-11 6Sirolimus 6Rituximab 6Letrozole 6Etoposide 6Cisplatin 6Aspirin 6olaparib 5Surveys and Questionnaires 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Indocyanine Green 5Granulocyte Colony-Stimulating Factor 5Fluorodeoxyglucose F18 5Dexamethasone 5aldesleukin 4Surgical Procedures, Operative 4Proflavine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Completed × Docosahexaenoic Acids × Clear all
NCT01881048 2026-01-29

Window of Opportunity Study Targeting the Inflammatory Milieu

University of Colorado, Denver

Phase EARLY_PHASE1 Completed
42 enrolled
Breast

Breast Neoplasms

NCT02538484 2023-07-17

Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Completed
24 enrolled
Breast

Breast Neoplasms

NCT02517502 2022-01-24

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

University of Kansas Medical Center

Phase EARLY_PHASE1 Completed
24 enrolled
Breast

Breast Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡